Aguirre at al. showed the feasibility and merit of performing high-quality genomic profiling in clinically relevant timelines (<35 days) and identified potentially actionable somatic and germline alterations in 48% of 71 patients analysed, including DDR gene mutations, KRAS wild-type tumours, BRAF alterations and ROS1 translocation [2]. The gene discussed is KRAS; the disease is neoplasm.